Thyroid Experts Warn of Clinically Important Differences in Potency of FDA-Approved Levothyroxine Products Generic bioequivalence…
Read More
Thyroid Experts Speak Out Against the FDA’s Decision to Approve Generic Levothyroxine Preparations FDA approval…
ATA, TES, and AACE express disappointment and concern for the health of millions of thyroid…
ATA and Endocrine Sister Societies urge FDA to consider expert opinion and the health of…
American Thyroid Association (ATA) Statement on Early Maternal Thyroidal Insufficiency: Recognition, Clinical Management and Research…
ATA, AACE and TES respond to FDA postponement of workshop March 19, 2004 Steven Galson,…
ATA Public Health Committee Statement February 3, 2004 An increasing concern has developed over the…
The ATA would like to highlight the findings from two recent publications on subclinical thyroid…
FDA Bioequivalence Workshop Plans continue with ATA, Endocrine Society and AACE leaders 2003-2004 President Clark…
Draft Levothyroxine Workshop Agenda Download Agenda (PDF File, 108 KB) See related articles on Bioequivalence…
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.